MIRA INFORM REPORT

 

 

Report Date :

15.10.2007

 

IDENTIFICATION DETAILS

 

Name :

VINATI ORGANICS LIMITED

 

 

Registered Office :

B – 12 and B – 13/1, MIDC Industrial Area, Mahad – 402309, District Raigad, Maharashtra

 

 

Country :

India

 

 

Financials (as on) :

31.03.2007

 

 

Date of Incorporation :

15.06.1989

 

 

Com. Reg. No.:

52224

 

 

CIN No.:

[Company Identification No.]

U24116MH1989PLC052224

 

 

TAN No.:

[Tax Deduction & Collection Account No.]

MUMV10590G

 

 

PAN No.:

[Permanent Account No.]

AAACV6538K

 

 

Legal Form :

Public Limited Liability Company. Company’s Shares are listed on Stock Exchange. 

 

 

Line of Business :

Manufacturing and exporting of premium organic intermediates and monomers.

 

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Maximum Credit Limit :

USD1100000

 

 

Status :

Satisfactory

 

 

Payment Behaviour :

Regular

 

 

Litigation :

Clear

 

 

Comments :

Subject is a well-established and reputed company having satisfactory track. Directors are reported as experience and respectable businessmen. Trade relations are reported as fair. Business is active. Payments are usually correct and as per commitments.

 

The company can be considered normal for business dealings at usual trade terms and conditions.

 

 

LOCATIONS

 

Registered Office /

Factory :

B – 12 and B – 13/1, MIDC Industrial Area, Mahad – 402309, District Raigad, Maharashtra, India

Tel. No.:

91-2145-232012/13/14

Fax No.:

91-2145-232010

E-Mail :

shares@vinatiorganics.com

vinmhd@vinatiorganics.com

Website :

http://www.vinatiorganics.com

 

 

Corporate Office :

Shiv – Ashish, 2nd Floor, Andheri – Kurla Road, Sakinaka, Mumbai – 400072, Maharashtra, India 

Tel. No.:

91-22-28510811

Fax No.:

91-22-28510729

E-Mail :

vinati@vinatiorganics.com

 

 

Factory :

Plot No. A-20, MIDC, Industrial Area, Lote Parashuram – 415722, Taluka – Khed, District – Ratnagiri, Maharashtra, India

Tel. No.:

91-2356-273032/33

E-Mail :

vinlote@vinatiorganics.com

 

 

Branches :

311,Paras chambers, 3-5-890, Himayath Nagar, Opp. Hyderabad Stock Exchange, Hyderabad-500 029.Andhra Pradesh, India

E-Mail :

vinhyd@vinatiorganics.com

 

 

DIRECTORS

 

Name :

Mr. Vinod Saraf

Designation :

Chairman and Managing Director

 

 

Name :

Mr. Girish M. Dave

Designation :

Director

 

 

Name :

Mr. C. B. Gokhale

Designation :

Director

 

 

Name :

Mr. A. A. Krishnan

Designation :

Director

 

 

Name :

Mr. Sunil Saraf

Designation :

Director

 

 

Name :

Ms. Vinati Saraf

Designation :

Executive Director

 

 

KEY EXECUTIVES

 

Name :

Mr. Gunvant S. Singhi

Designation :

Company Secretary and Finance Controller

 

 

MAJOR SHAREHOLDERS / SHAREHOLDING PATTERN

 

Names of Shareholders

No. of Shares

Percentage of Holding

Individuals

1713907

26.04

Promoters

4529007

68.80

Other Companies

335330

5.08

Non-Resident Individuals

2356

0.04

Nationalized Banks, Mutual Funds and Trusts

2400

0.04

Total

6583000

100.00

 

 

BUSINESS DETAILS

 

Line of Business :

Manufacturing and exporting of premium organic intermediates and monomers.

 

 

Products :

Product Description:

Item Code No.

Isobutyl Benzene

2902.9050

2 Acrylamido 2Methylpropane Sulphonic Acid

2924.1900

 

PRODUCTION STATUS

 

Particulars

Unit

 

Installed Capacity

Actual Production

Isobutyl Benzene

M.T.

 

10000.00

6626.85

2 Acrylamido 2Methylpropane Sulphonic Acid

M.T.

 

3000.00

1808.17*

 

 

GENERAL INFORMATION

 

Suppliers :

  • Deepson Valves & Controls
  • Fuelpack Boilers & Engineering India Private Limited
  • KSD Technologies
  • Liberty Valve Private Limited
  • Tri- Flp Engineers Private Limited
  • Swellore Engineering Private Limited
  • Pluto Plastics Private Limited
  • Super Mechnical Seal Private Limited
  • Fainger Engineering
  • H K Industries
  • Leakpro of Engineering India Private Limited
  • R. K. Dutta Consorns
  • Sigma Seals
  • Arem Engineers
  • Inmarco Industrial Maintenance Private Limited
  • Universal Pollution Control India Private Limited

 

 

No. of Employees :

300

 

 

Bankers :

State Bank of India

 

 

Facilities :

SECURED LOANS :

 

Rs. In Millions

i) Term loan from Technology Development Board (TDB)

54.000

ii) Working capital advances from Bank

156.403

Notes :

1. Loan from TDB is secured by first charge on all the fixed assets (present and future) of Lote works, second charge on Current Assets, save and except book debts of the Company and also by personal irrevocable guarantee of the Managing Director and One more Director and Corporate Guarantee of

the Company.

 

2. Working Capital Advances from Bank are secured by hypothecation of inventories, all the present and future book debts & other receivables, first charge on all present and future fixed assets situated at Mahad works and Residential Buildings at Mahad and second charge on all fixed assets situated at Lote works and personal guarantee of two Directors.

 

3. Loans falling due within one year Rs.21.600 Millions

 

 

UNSECURED LOANS :

 

 

ICICI -Spread Loan

5.000

From a Director

0.143

Inter Corporate Deposits

41.358

 

 

 

Banking Relations :

Satisfactory

 

 

Auditors :

 

Name :

Karnavat and Company

Chartered Accountants

Address :

Mumbai, Maharashtra, India

 

 

Associates/Subsidiaries :

  • Viral Alkalis Limited
  • Vinati Wax Industries Private Limited
  • Shilpa Pharma Private Limited
  • Mithali Chemicals Private Limited
  • Viral Chemicals Private Limited
  • Viral Pharma Private Limited
  • Suchir Chemicals Private Limited
  • Suchir Investment & Finance Private Limited
  • Manan Pharma Private Limited
  • Mishit Pharma Chem Private Limited
  • Kavita Organics Private Limited

 

 

CAPITAL STRUCTURE

 

Authorised Capital :

No. of Shares

Type

Value

Amount

15,000,000

Equity Shares

Rs. 10/- each

Rs. 150.000 Millions

 

Issued, Subscribed & Paid-up Capital :

No. of Shares

Type

Value

Amount

6,583,000

Equity Shares

Rs. 10/- each

Rs. 65.830 Millions

 


 

 

FINANCIAL DATA

[all figures are in Rupees Millions]

 

 

ABRIDGED BALANCE SHEET

 

SOURCES OF FUNDS

 

31.03.2007

31.03.2006

31.03.2005

SHAREHOLDERS FUNDS

 

 

 

1] Share Capital

65.830

65.830

65.800

2] Share Application Money

0.000

0.000

0.000

3] Reserves & Surplus

233.175

207.279

195.300

4] (Accumulated Losses)

0.000

0.000

0.000

NETWORTH

299.005

273.109

261.100

LOAN FUNDS

 

 

 

1] Secured Loans

210.403

190.887

160.300

2] Unsecured Loans

46.501

34.063

0.200

TOTAL BORROWING

256.904

224.950

160.500

DEFERRED TAX LIABILITIES

48.410

46.648

0.000

 

 

 

 

TOTAL

604.319

544.707

421.600

 

 

 

 

APPLICATION OF FUNDS

 

 

 

 

 

 

 

FIXED ASSETS [Net Block]

359.878

366.936

319.300

Capital work-in-progress

16.340

3.864

7.400

 

 

 

 

INVESTMENT

0.000

0.000

0.000

DEFERREX TAX ASSETS

0.000

0.000

0.000

 

 

 

 

CURRENT ASSETS, LOANS & ADVANCES

 

 

 

 

Inventories

82.080

78.902

89.200

 

Sundry Debtors

197.015

132.626

82.200

 

Cash & Bank Balances

8.796

13.811

5.200

 

Other Current Assets

0.000

0.000

0.000

 

Loans & Advances

57.159

30.572

42.900

Total Current Assets

345.050

255.911

219.500

Less : CURRENT LIABILITIES & PROVISIONS

 

 

 

 

Current Liabilities

103.894

73.359

115.500

 

Provisions

13.055

8.645

9.100

Total Current Liabilities

116.949

82.004

124.600

Net Current Assets

228.101

173.907

94.900

 

 

 

 

MISCELLANEOUS EXPENSES

0.000

0.000

0.000

 

 

 

 

TOTAL

604.319

544.707

421.600

 


PROFIT & LOSS ACCOUNT

 

PARTICULARS

 

31.03.2007

31.03.2006

31.03.2005

 

 

 

 

Sales Turnover

820.486

573.522

563.700

Other Income

18.865

7.830

29.800

Total Income

839.351

581.352

593.500

 

 

 

 

Profit/(Loss) Before Tax

55.268

29.563

46.800

Provision for Taxation

20.130

10.028

14.900

Profit/(Loss) After Tax

35.138

19.535

31.900

 

 

 

 

Earnings in Foreign Currency :

 

 

 

 

Export Earnings

429.700

159.514

NA

Total Earnings

429.700

159.514

NA

 

 

 

 

Imports :

 

 

 

 

Raw Materials

82.408

41.051

NA

Total Imports

82.408

123.459

NA

 

 

 

 

Expenditures :

 

 

 

 

Raw Material Consumed

543.205

371.951

340.100

 

Increase/(Decrease) in Finished Goods

8.341

25.671

0.000

 

Salaries, Wages, Bonus, etc.

52.853

42.931

37.700

 

Manufacturing Expenses

65.879

40.307

19.500

 

Administrative  and Other Expenses

86.491

46.980

149.400

Total Expenditure

756.769

527.840

546.700

 

 

 

QUARTERLY RESULTS

 

PARTICULARS

 

 

 

30.06.2007

Type

 

 

1st Quarter

Sales Turnover

 

 

279.300

Other Income

 

 

3.700

Total Income

 

 

283.000

Total Expediture

 

 

238.100

Operating Profit

 

 

44.900

Interest

 

 

7.800

Gross Profit

 

 

37.100

Depreciation

 

 

7.000

Tax

 

 

10.400

Reported PAT

 

 

19.600

 

KEY RATIOS

 

PARTICULARS

 

31.03.2007

31.03.2006

31.03.2005

Debt-Equity Ratio

0.84

0.72

0.61

Long Term Debt-Equity Ratio

0.24

0.33

0.36

Current Ratio

0.95

1.03

1.23

TURNOVER RATIOS

 

 

 

Fixed Assets

1.64

1.29

1.30

Inventory

11.24

7.76

7.66

Debtors

5.49

6.07

6.75

Interest Cover Ratio

3.81

3.39

8.20

Operating Profit Margin(%)

11.29

10.09

12.88

Profit Before Interest And Tax Margin(%)

8.29

6.44

9.46

Cash Profit Margin(%)

6.88

6.64

9.08

Adjusted Net Profit Margin(%)

3.88

2.99

5.66

Return On Capital Employed(%)

14.23

9.13

13.30

Return On Net Worth(%)

12.27

7.30

12.82

 

 

LOCAL AGENCY FURTHER INFORMATION

 

 

REVIEW OF OPERATIONS 

 
Members will be pleased to note that the operations of the company have shown satisfactory performance. For the year under review sales have gone up by 1292.87 metric tons in terms of quantity and about Rs. 252.629 Millions in terms of value. The profitability has gone up due to management's thrust on exports, which have gone up by a healthy Rs. 282.359 Millions during the year. 

PROSPECTS 
 
The project work on the proposed modernization-cum-expansion programme is on schedule. The project aims at establishing manufacturing facilities to match International Standards. After full implementation, the production capacity of the company will also go up. 

The company has gone under new expansion and diversification programme and also continued to see strong and profitable growth in the financial year 2006-2007 across all markets driven by good performance in existing and new areas of business. 

(i) Expansion of IBB Plant at Mahad 

In order to cater increased export demand, the Company has undertaken expansion of IBB plant to increase the capacity from 10000 TPA to 14000 TPA. (Increment of 40%). 

(ii) Expansion of 2-Acrylamido 2 Methylpropane Sulfonic Acid (ATBS) Plant at Lote 

In order to cater higher exports demand, the Company is planning to increase existing capacity from 3000 TPA to 8000 TPA. (Increment of approx. 166.66 %) 

The matter of concern is the steep rise in Indian rupee vis-a-vis US Dollar. However the management is taking judicious decisions to safeguard the Company's interest. 

(i) Mr. A.A. Krishnan, Chemical Engineer 

Mr. A. A. Krishnan has very wide experience in Petrochemical industry. He is Director of other Public Limited Companies namely Andhra Petrochemicals Limited and Petron Engineering Construction Limited. The Company has benefited by his 45 years of experience. He was appointed as a director long back and has vast and diversified technological and chemical expertise of running the manufacturing unit in such industries. Due to his commitment for technological advancement in continuously improving the systems and procedures, he has substantially contributed to the growth of the Company.

Therefore with a view to get benefit out of his past experience and technical competence, the Board recommends his reappointment. 

 
(ii) Mr. Girish M. Dave, M Com, L.L.B. & CAIIB 

Mr. Girish M. Dave is an eminent advocate and senior partner of the well-known Law Firm M/s. Dave & Girish & Company, Advocates and has over 40 years experience in the legal field. The Company has benefited substantially from his advice and guidance and also due to his immense knowledge in the said field he has contributed to the Company with a wide range of advancement in the respective fields so as to reap the fruitful benefit in the long run. He has served on the Board of the company and has given valuable advice on legal and administrative matters to the management. Therefore with a view to his contribution, the Board recommends his reappointment. 

MANAGEMENT'S DISCUSSION AND ANALYSIS REPORT 

1. INDUSTRY STRUCTURE, DEVELOPMENTS AND OUTLOOK 

Isobutyl Benzene (IBB) 

IBB is the basic ingredient of Ibuprofen, an anti-inflammatory and analgesic bulk drug. India is a net exporter of both IBB and Ibuprofen. The world market for Ibuprofen is estimated to grow at 5-6% annually.

2-Acrylamido-2-Methylpropane Sulfonic Acid (ATBS), Sodium salt of ATBS (Na-ATBS), N-tert-Butylacrylamide TBA)  

These specialty monomers have wide applications mainly in oil-field recovery, water treatment, acrylic fiber manufacturing, adhesives and personal care products. They are also used in mining industry, coatings and as dispersing and flocculating agents. Globally, the demand for these products is growing as newer applications are being developed based on these monomers. There are very few manufacturers of these products world-wide. With the growth of the above industries in India, these products will find new applications domestically. The world market for these products is growing rapidly. 

2. 'SWOT' Analysis 

STRENGTHS & OPPORTUNITIES 

- 15 years of manufacturing experience with world class, inimitable technology 

- Proximity to Mumbai and JNPT port provides great ease of logistics and access to advanced infrastructure facilities. 

 - State of the Art, competitive and cost effective manufacturing. 

 - Environment friendly operations including waste product recycling. 

 - Fully equipped laboratories with high - tech advanced instruments and highly qualified technical personnel. 

- Commitment to manufacturing quality products using GMP as per internationally accepted norms 

 - Growing export market 

- India emerging as a global hub for pharma / agro intermediates. 

- Superior product and customer satisfaction 

- Growth by adding value to customers 

- Long-term business associations. IBB 

- The Company is the world's largest manufacturer and supplier of IBB. 

- The manufacturing costs are significantly lower in India and the Company has employed efficient manufacturing practices. Thus it has been able to capture market-share from domestic IBB producers worldwide. 

- Market share of Indian Ibuprofen manufacturers is increasing globally. As a result domestic demand and prices for IBB are expected to rise. 

- The Company has entered into a long-term supply agreement with BASF Corporation, USA, World's largest producer of Ibuprofen. 

- The supply agreement warrants BASF to buy majority of its IBB requirements from the Company up to 2011. 

- According to the agreement the monthly selling price of IBB is adjusted based on monthly world prices of key raw materials and USD / INR exchange rate, thus minimizing the Company's exposure to these variables. 
 
ATBS / Na-ATBS & TBA 

- The technology to manufacture these products is scarce. Currently there are only 2 other major producers of these monomers in the world. 

- As suppliers of these products are limited, customers are very keen to work for a new source of supply. 

- All the major users of these products are based in Europe or U.S.A., thus they prefer to enter into annual contracts. 
 
- Due to manufacturing and cost advantages as well as consistent sales efforts, the Company has been successful in establishing long-term contracts with World's largest buyers based in USA and Europe
 
- The Company has also undertaken an application development program and has successfully initiated business in new user industries in the domestic market. 

- The Company is conducting an expansion programme thereby increasing capacity from 3000 TPA to 8000 TPA 
 
 - The world demand for these monomers is growing rapidly, which is expected to increase 2 to 3 folds with the production of enhanced oil recovery polymers. 

FIXED ASSETS

  • Leasehold Land & Site Development
  • Buildings
  • Plant & Machinery
  • Furniture & Fixtures
  • Office Equipments
  • Computers
  • Air Conditioners
  • Vehicles

AS PER WEBSITE

Profile

Subject is a public limited company, listed with Bombay Stock Exchange producing specialty organic intermediates and monomers.

Subject has over 300 employees working in fully computerized, modern day production facilities at The MIDC Industrial Areas in Mahad and Lote Parshuram, which are among the best industrial areas in Maharashtra with well developed infrastructure accommodating various large scale Petrochemical, Chemical & Textile industries.

Subject started commercial production at its first unit in Mahad, which was installed in technical collaboration with Institut Francais du Petrole (IFP), France, the world leaders in the petrochemical field. VOL has successfully absorbed this technology to become the world's largest producer of best quality Iso-ButylBenzene(IBB) and N-Butylbenzene(NBB). IBB is an organic intermediate mainly used to manufacture Ibuprofen, a widely used drug, while NBB is a specialty solvent and has applications in LCD and chemical synthesis.

Subject started commercial production at its second unit installed in Lote Parshuram and became the third company in the world to manufacture specialty monomers, 2-Acrylamido 2-methylpropanesulfonic Acid. The plant was installed based on breakthrough technology developed with the aid of National Chemical Laboratories (NCL), Pune. ATBS is a co-monomer having applications is acrylic fiber, water treatment, emulsions, paints and oil field drilling industries.

Subject had sales of Rs. 651.900 million for year 2005-2006 with an increase of 15.66% in sales, with net profit of Rs. 41.49 million. They have achieved sales of Rs. 609.400 with gross profit of Rs. 61.800 million in nine months i.e. March 2006-December 2006.

Subject's substantial growth is mainly attributed to its efficient manufacturing and sales practices.

Products

Isobutylbenzene (IBB)

Applications

  • Basic raw material for manufacturing Ibuprofen, an Anti-inflammatory analgesic bulk drug.
  • It is used in Perfume industry.
  • It is also used as a speciality solvent 

Normal Butylbenzene (NBB)

Applications

  • Used as speciality solvent.
  • Synthesis of intermediate
  • Application in LCD.

2-Acrylamido 2-methylpropanesulfonic Acid

Applications

  • Co Monomer in Acrylic Fiber Industry.
  • Co Monomer in Textiles, Photography.
  • Oil Industry (Drilling, Mud, Additives, Oil enhance, recovery, oil well).
  • Water Treatment - Corrosion inhibitor silt control.
  • Paper and Pulp- Filter aid sizing dispersant.
  • In Mining as Flocculants.

 

                                                                               

 

Sodium Salt of 2-Acrylamido 2-methylpropanesulfonic Acid

Applications

  • Co Monomer in Acrylic Fiber Industry.
  • Co Monomer in Textiles, Photography.
  • Oil Industry ( Drilling, Mud, Additives, Oil enhance, recovery, oil well .
  • Water Treatment - Corrosion inhibitor silt control.
  • Paper and Pulp- Filter aid sizing dispersant.
  • In Mining as Flocculants.

4-n-Butylaniline (Para- n-Butylaniline)

                                                                               

2-n-Butylaniline (Ortho-n-Butylaniline)

 

n-Tertiary Butyl Acrylamide (TBA)

Applications

  • Photo.
  • Monomer for cosmetics.
  • Monomer for Acrylic Ploymers.
  • Adhesives.

Press Release June - 2007

Vinati organics Limited has reported the results for the year ended 31st March 2007, showing a Turnover of Rs. 904.622 Millions and Net Profit of Rs. 35.139 Millions, an increase of 39% and 80% respectively compared to the corresponding previous year ended 31st March 2006. The board recommended payment of Dividend of 12% per share. EPS for the year ended 31st March 2007 is Rs. 5.34 as compared to Rs. 2.97 for the previous year ended 31st March 2006.

In order to cater higher exports demand, the company has undertaken expansion of IBB (Isobutyl Benzene) plant to increase the capacity to 12000 TPA from 10000 TPA and the Company is also planning to increase existing capacity of ATBS (2-Acrylamido 2-methylpropanesulfonic Acid) from 2500 TPA to 8000 TPA.

 Good news for Indian Polymer Manufacturers

 

Add value to the water soluble Polymers polarity to the finished Polymer System Hydrolic, Mechanical & Thermal stability increase divalant cation tolerance Hydrophilicity & Lubricity without adding much cost by adding their 2-Acrylamido-2-Methyl-1-Propane Sulphonic Acid as Co-monomer with Acrylamide; Used for making water soluble Polymers for Oil Field and Water Treatment etc.

 

 


CMT REPORT (Corruption, Money Laundering & Terrorism]

 

The Public Notice information has been collected from various sources including but not limited to: The Courts, India Prisons Service, Interpol, etc.

 

1]         INFORMATION ON DESIGNATED PARTY

No records exist designating subject or any of its beneficial owners, controlling shareholders or senior officers as terrorist or terrorist organization or whom notice had been received that all financial transactions involving their assets have been blocked or convicted, found guilty or against whom a judgement or order had been entered in a proceedings for violating money-laundering, anti-corruption or bribery or international economic or anti-terrorism sanction laws or whose assets were seized, blocked, frozen or ordered forfeited for violation of money laundering or international anti-terrorism laws.

 

2]         Court Declaration :

No records exist to suggest that subject is or was the subject of any formal or informal allegations, prosecutions or other official proceeding for making any prohibited payments or other improper payments to government officials for engaging in prohibited transactions or with designated parties.

 

3]         Asset Declaration :

No records exist to suggest that the property or assets of the subject are derived from criminal conduct or a prohibited transaction.

 

4]         Record on Financial Crime :

            Charges or conviction registered against subject:                                                  None

 

5]         Records on Violation of Anti-Corruption Laws :

            Charges or investigation registered against subject:                                                          None

 

6]         Records on Int’l Anti-Money Laundering Laws/Standards :

            Charges or investigation registered against subject:                                                          None

 

7]         Criminal Records

No available information exist that suggest that subject or any of its principals have been formally charged or convicted by a competent governmental authority for any financial crime or under any formal investigation by a competent government authority for any violation of anti-corruption laws or international anti-money laundering laws or standard.

 

8]         Affiliation with Government :

No record exists to suggest that any director or indirect owners, controlling shareholders, director, officer or employee of the company is a government official or a family member or close business associate of a Government official.

 

9]         Compensation Package :

Our market survey revealed that the amount of compensation sought by the subject is fair and reasonable and comparable to compensation paid to others for similar services.

 

10]        Press Report :

            No press reports / filings exists on the subject.

 

 

CORPORATE GOVERNANCE

 

MIRA INFORM as part of its Due Diligence do provide comments on Corporate Governance to identify management and governance. These factors often have been predictive and in some cases have created vulnerabilities to credit deterioration.

 

Our Governance Assessment focuses principally on the interactions between a company’s management, its Board of Directors, Shareholders and other financial stakeholders.

 

 

CONTRAVENTION

 

Subject is not known to have contravened any existing local laws, regulations or policies that prohibit, restrict or otherwise affect the terms and conditions that could be included in the agreement with the subject.

 

 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.39.31

UK Pound

1

Rs.79.95

Euro

1

Rs.55.71

 

 

SCORE & RATING EXPLANATIONS

 

SCORE FACTORS

 

RANGE

POINTS

HISTORY

1~10

6

PAID-UP CAPITAL

1~10

6

OPERATING SCALE

1~10

6

FINANCIAL CONDITION

 

 

--BUSINESS SCALE

1~10

7

--PROFITABILIRY

1~10

5

--LIQUIDITY

1~10

6

--LEVERAGE

1~10

6

--RESERVES

1~10

6

--CREDIT LINES

1~10

6

--MARGINS

-5~5

-

DEMERIT POINTS

 

 

--BANK CHARGES

YES/NO

YES

--LITIGATION

YES/NO

NO

--OTHER ADVERSE INFORMATION

YES/NO

NO

MERIT POINTS

 

 

--SOLE DISTRIBUTORSHIP

YES/NO

NO

--EXPORT ACTIVITIES

YES/NO

YES

--AFFILIATION

YES/NO

YES

--LISTED

YES/NO

NO

--OTHER MERIT FACTORS

YES/NO

YES

TOTAL

 

54

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

 


 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Unfavourable & favourable factors carry similar weight in credit consideration. Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

NR

In view of the lack of information, we have no basis upon which to recommend credit dealings

No Rating

 

 

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions